Join us for an educational workshop on the diagnosis, treatment and monitoring of plasma cell malignancies, including current practices and opportunities for improvement.

The workshop will include lectures plus roundtable discussions around the most hot and controversial topics, featuring point-counterpoint conversations between invited speakers and local hematologists based on both challenging questions and clinical cases.

Numerous networking opportunities will also be available in order to establish potential collaborations among speakers and participants.

In support of improving patient care, this activity has been planned and implemented by Mayo Clinic College of Medicine and Science and International Myeloma Society. Mayo Clinic College of Medicine and Science is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Mayo Clinic College of Medicine and Science designates this live activity for a maximum of 11.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

*This activity is supported by an educational grant from Sanofi Genzyme.*

**FEATURED SPEAKERS:**

**SATURDAY**

**Multiple Myeloma: A journey through decades**

Robert A. Kyle, MD  
Mayo Clinic  
Rochester, MN

**SUNDAY**

**The future of therapy in myeloma?**

Kenneth C. Anderson, MD  
Dana-Farber Cancer Institute  
Boston, MA
Saturday, September 15, 2018

08:15-08:30  Welcome and introduction

08:30-9:00  Multiple Myeloma: A journey through decades
           Robert Kyle, MD

9:00-9:30  Multiple Myeloma: Novel Biologic Insights
           Nikhil Munshi, MD

9:30-10:00  Tracking Genetic Heterogeneity
           Jens Lohr, MD

10:00-10:30  Coffee Break

10:30-11:00  Implementing appropriate tests for follow up and treatment decisions: serum markers and imaging
           Ajay Nooka, MD

11:00-11:30  Minimal residual Disease. How and when to do it?
           Phil McCarthy, MD

11:30-12:00  Roundtable: How to do a correct diagnosis and follow-up: Controversial cases with emphasis on local practice
           Moderator: Nikhil Munshi, MD
           Discussants: Jens Lohr, MD, , Ajay Nooka, MD, Phil McCarthy, MD, Kenneth Shain, MD

12:00-13:00  Lunch

13:00-13:30  MGUS & Smoldering Myeloma: Risk Stratification and Therapeutic Options
           Natalie Callander, MD

13:30-15:30  How I treat newly diagnosed transplant eligible MM patients?

13:30-13:50  The best induction and risk adapted approaches for initial therapy in myeloma
           Ravi Vij, MD

13:50-14:10  Role of autologous stem cell transplant
           Hari Parameswaran, MD

14:10-14:30  Role of consolidation and maintenance?
           Sundar Jagannath, MD

14:30-14:50  Allogeneic stem cell transplant in myeloma: is there still a role?
           Sergio Giralt, MD

14:50-15:30  Roundtable: Optimizing the use of stem cell transplant in myeloma Controversial cases presented by local physicians with emphasis on local practice
           Moderator: Sundar Jagannath, MD
           Discussants: Sundar Jagannath, MD, Sergio Giralt, MD, Hari Parameswaran, MD, Kenneth Anderson, MD, Melissa Alsina, MD

15:30-16:00  Coffee Break

16:00-16:30  Management of Renal Disease in monoclonal gammopathies
           Nelson Leung, MD

16:30-17:00  Management of Bone disease and other supportive care Strategies
           Matthew Drake, MD
Sunday, September 16, 2018

8:00-8:30  The future of therapy in myeloma?  
Kenneth Anderson, MD

8:30-9:40  How I treat newly diagnosed elderly patients?

8:30-8:50  What is the ideal initial therapy for the older patient?  
Elizabeth O’Donnell, MD

8:50-9:10  How should we adapt therapy for the elderly?  
Ravi Vij, MD

9:10-9:40  Roundtable: Controversial elderly cases with emphasis on US practice  
Moderator: Melissa Alsina, MD  
Discussants: Ravi Vij, MD, Jacob Laubach, MD, Elizabeth O’Donnell, MD, Nikhil Munshi, MD, Sundar Jagannath, MD

9:40-10:10  Coffee Break

10:10-11:30  How to make the right choices in the relapsed patient?  

10:10-10:30  How do we manage early relapse  
Sagar Lonial, MD

10:30-10:50  Approaches for refractory relapsed myeloma  
Robert Orlowski, MD

10:50-11:30  Roundtable: Controversial cases with emphasis on US practice  
Moderator: Sagar Lonial, MD  
Discussants: Ravi Vij, MD, Sundar Jagannath, MD, Robert Orlowski, MD, Phil McCarthy, MD

11:30-12:00  Amyloidosis: “Under-diagnosed disorder”  
Suzanne Lentsch, MD

12:00-12:30  Waldenström Macroglobulinemia  
Jorge Castillo, MD

12:30-13:00  Immunotherapy including CAR T cells  
Adam Cohen, MD

13:00-13:30  Novel Drug Targets in Clinical Trials  
Andrew Yee, MD

THANK YOU TO OUR SPONSORS

Gold

Silver

Additional Support Provided By